Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $7,000,560.00 in Stock

Posted by Latisha Jones on Oct 9th, 2026

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 72,000 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $97.23, for a total value of $7,000,560.00. Following the transaction, the chief executive officer owned 108,209 shares of the company’s stock, valued at approximately $10,521,161.07. This represents a 39.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The shares were sold at an average price of $95.86, for a total value of $2,300,640.00.
On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total value of $2,033,010.00.
On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00.
On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00.
On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total value of $3,347,980.00.
On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.

BioNTech Stock Down 3.3%

BNTX stock opened at $92.06 on Friday. The firm’s 50-day moving average is $99.04 and its two-hundred day moving average is $95.16. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $23.28 billion, a price-to-earnings ratio of -11.76 and a beta of 1.25. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00.

BioNTech (NASDAQ:BNTX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.60) EPS. On average, analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, October 2nd. UBS Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Finally, Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $125.69.

Read Our Latest Stock Analysis on BioNTech

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC increased its position in shares of BioNTech by 31.5% in the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after acquiring an additional 118 shares in the last quarter. Quintet Private Bank Europe S.A. boosted its position in BioNTech by 232.8% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after acquiring an additional 1,341 shares during the period. Engineers Gate Manager LP boosted its holdings in shares of BioNTech by 17.3% during the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock worth $1,157,000 after purchasing an additional 1,833 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech during the 2nd quarter valued at $39,000. Finally, Nykredit A S purchased a new position in BioNTech in the second quarter valued at about $293,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.